Intercept Pharmaceuticals Profit Margin

The latest profit margin for ICPT is -20.49% as of September 2023. That compares with 62.47% in the prior-year period — down 132.8% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Intercept Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ICPT's profit margin moved from 62.47% to -20.49% — a 132.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intercept Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, ICPT currently prints -20.49% for profit margin, while the sector average sits near 15.58%. That is roughly 231.5% below the sector mean. Large gaps often invite a closer look at Intercept Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Intercept Pharmaceuticals converts resources into returns. At -20.49%, ICPT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 62.47% in the prior-year period — down 132.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ICPT's profit margin (-20.49%), review year-over-year change from 62.47%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.